Research

M Perera, G Jibara,Ã‚Â A Tin, S Haywood, D Sjoberg, N Benfante, S Carlsson, J Eastham, V Laudone, K Touijer, S Fine, P Scardino, A Vickers, B Ehdaie
Outcomes of Grade Group 2 and 3 prostate cancer on initial versus confirmatory biopsy: Implications for active surveillance
European Urology Focus. 2022, In Press

This study compares outcomes between men with Grade Group (GG) 2/3 prostate cancer diagnosed on initial biopsy and those initially diagnosed with GG1 but upgraded to GG2/3 on confirmatory biopsy during active surveillance (AS).

The results show that men in the AS group had lower rates of adverse pathology (27% vs. 35%) and biochemical recurrence (BCR) compared to those who underwent immediate radical prostatectomy (RP) with GG2/3 cancer. The AS group also had better risk-adjusted BCR rates at 1 and 5 years.

These findings suggest that men upgraded on confirmatory biopsy may have less aggressive disease than those diagnosed with higher grades initially, but further studies are needed to confirm these results.

Read the full article

Dr. Marlon Perera

Dr. Marlon Perera is an Australian-trained, award-winning urology surgeon who specialises in robotic surgery and uro-oncology. Dr. Perera has worldwide experience, having completed a PhD (Urology) and a prized-accredited ‘Society of Urologic Oncology’ (SUO) fellowship at one of the world’s best and most prestigious cancer centres – Memorial Sloan Kettering Cancer Center in New York City. He provides comprehensive care in the treatment of prostate cancer, kidney masses and cancers, bladder cancer, kidney stones, and voiding dysfunction.